» Articles » PMID: 32154731

Polygenic Hyperlipidemias and Coronary Artery Disease Risk

Abstract

Background: Hyperlipidemia is a highly heritable risk factor for coronary artery disease (CAD). While monogenic familial hypercholesterolemia associates with severely increased CAD risk, it remains less clear to what extent a high polygenic load of a large number of LDL (low-density lipoprotein) cholesterol (LDL-C) or triglyceride (TG)-increasing variants associates with increased CAD risk.

Methods: We derived polygenic risk scores (PRSs) with ≈6M variants separately for LDL-C and TG with weights from a UK Biobank-based genome-wide association study with ≈324K samples. We evaluated the impact of polygenic hypercholesterolemia and hypertriglyceridemia to lipid levels in 27 039 individuals from the National FINRISK Study (FINRISK) cohort and to CAD risk in 135 638 individuals (13 753 CAD cases) from the FinnGen project (FinnGen).

Results: In FINRISK, median LDL-C was 3.39 (95% CI, 3.38-3.40) mmol/L, and it ranged from 2.87 (95% CI, 2.82-2.94) to 3.78 (95% CI, 3.71-3.83) mmol/L between the lowest and highest 5% of the LDL-C PRS distribution. Median TG was 1.19 (95% CI, 1.18-1.20) mmol/L, ranging from 0.97 (95% CI, 0.94-1.00) to 1.55 (95% CI, 1.48-1.61) mmol/L with the TG PRS. In FinnGen, comparing the highest 5% of the PRS to the lowest 95%, CAD odds ratio was 1.36 (95% CI, 1.24-1.49) for the LDL-C PRS and 1.31 (95% CI, 1.19-1.43) for the TG PRS. These estimates were only slightly attenuated when adjusting for a CAD PRS (odds ratio, 1.26 [95% CI, 1.16-1.38] for LDL-C and 1.24 [95% CI, 1.13-1.36] for TG PRS).

Conclusions: The CAD risk associated with a high polygenic load for lipid-increasing variants was proportional to their impact on lipid levels and partially overlapping with a CAD PRS. In contrast with a PRS for CAD, the lipid PRSs point to known and directly modifiable risk factors providing additional guidance for clinical translation.

Citing Articles

Genetic risk score for coronary artery calcification and its predictive ability for coronary artery disease.

Mishra P, Mishra B, Lyytikainen L, Goebeler S, Martiskainen M, Hakamaa E Am J Prev Cardiol. 2024; 20:100884.

PMID: 39483246 PMC: 11525111. DOI: 10.1016/j.ajpc.2024.100884.


LCoRL Regulates Growth and Metabolism.

Wyler S, Gahlot S, Bideyan L, Yip C, Dushime J, Chen B Endocrinology. 2024; 165(12).

PMID: 39467326 PMC: 11538781. DOI: 10.1210/endocr/bqae146.


Regulation of Mitochondria-Derived Immune Activation by 'Antiviral' TRIM Proteins.

Oh S, Mandell M Viruses. 2024; 16(7).

PMID: 39066323 PMC: 11281404. DOI: 10.3390/v16071161.


Inferring causal direction between two traits using R with application to transcriptome-wide association studies.

Liao H, Xue H, Pan W Am J Hum Genet. 2024; 111(8):1782-1795.

PMID: 39053457 PMC: 11339628. DOI: 10.1016/j.ajhg.2024.06.013.


Obstructive Sleep Apnea Syndrome Exacerbates NASH Progression via Selective Autophagy-Mediated Eepd1 Degradation.

Xiong J, Xu Y, Wang N, Wang S, Zhang Y, Lu S Adv Sci (Weinh). 2024; 11(35):e2405955.

PMID: 38924647 PMC: 11425227. DOI: 10.1002/advs.202405955.


References
1.
Di Angelantonio E, Sarwar N, Perry P, Kaptoge S, Ray K, Thompson A . Major lipids, apolipoproteins, and risk of vascular disease. JAMA. 2009; 302(18):1993-2000. PMC: 3284229. DOI: 10.1001/jama.2009.1619. View

2.
Fulcher J, OConnell R, Voysey M, Emberson J, Blackwell L, Mihaylova B . Efficacy and safety of LDL-lowering therapy among men and women: meta-analysis of individual data from 174,000 participants in 27 randomised trials. Lancet. 2015; 385(9976):1397-405. DOI: 10.1016/S0140-6736(14)61368-4. View

3.
Do R, Willer C, Schmidt E, Sengupta S, Gao C, Peloso G . Common variants associated with plasma triglycerides and risk for coronary artery disease. Nat Genet. 2013; 45(11):1345-52. PMC: 3904346. DOI: 10.1038/ng.2795. View

4.
Talmud P, Shah S, Whittall R, Futema M, Howard P, Cooper J . Use of low-density lipoprotein cholesterol gene score to distinguish patients with polygenic and monogenic familial hypercholesterolaemia: a case-control study. Lancet. 2013; 381(9874):1293-301. DOI: 10.1016/S0140-6736(12)62127-8. View

5.
Abul-Husn N, Manickam K, Jones L, Wright E, Hartzel D, Gonzaga-Jauregui C . Genetic identification of familial hypercholesterolemia within a single U.S. health care system. Science. 2016; 354(6319). DOI: 10.1126/science.aaf7000. View